After a ten-year long criminal investigation, Johnson & Johnson has entered a guilty plea and will pay $2.2 billion in damages. The U.S. Department of Justice charged the company with promoting the drugs Risperdal and Invega for off-label uses (uses that were not approved by the FDA). These drugs were approved solely for the treatment of schizophrenia, but Johnson & Johnson was promoting them for non-schizophrenic patients—including children, ...
continue reading...Johnson & Johnson Guilty Plea Helps Risperdal Lawsuits
Posted November 19, 2013 in Health | Product Liability | Product News and Recalls | Verdicts & Settlements
J&J to Pay Over $2.2 Billion in False Marketing Settlement
Posted November 11, 2013 in Drug and Medical Device Lawsuits | Product News and Recalls | Verdicts & Settlements
Johnson & Johnson (J&J) and its subsidiaries have agreed to pay over $2.2 billion in criminal and civil fines arising out of false marketing claims. The company allegedly promoted off-label uses for various drugs, and provided kickbacks to doctors and pharmacists for prescribing those drugs. The drugs at issue in this suit include Risperdal, Invega (forms of antipsychotic medications), and Natrecor (heart ...
